drugset / Trial / NCT06310876
A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects
RandomizedCrossoverDouble-blindBasic science
Summary
This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects.
Timeline
- Start
- 2024-03-14
- Primary completion
- 2024-05-29
- Completion
- 2024-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABBV-CLS-7262 | Unknown | — | Oral |
| Subject | Moxifloxacin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.